| Source: |
| Type: |
| The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
| Pancreatic Cancer: Hypoxia (low oxygen tension) is commonly found in solid tumors. Hypoxia-inducible factor-1 (HIF-1),is a key mediator of the cellular response to hypoxia and is overexpressed in a wide variety of solid tumors, including pancreatic cancer. Nanog is highly expressed in CSCs compared to normal cells [93–97] HIF-1↑ |
| 5280- | 3BP, | Anticancer Efficacy of the Metabolic Blocker 3-Bromopyruvate: Specific Molecular Targeting |
| - | in-vitro, | PC, | NA |
| 5277- | 3BP, | 3-Bromopyruvate inhibits pancreatic tumor growth by stalling glycolysis, and dismantling mitochondria in a syngeneic mouse model |
| - | in-vivo, | PC, | Panc02 |
| 4411- | AgNPs, | Eco-friendly synthesis of silver nanoparticles using Anemone coronaria bulb extract and their potent anticancer and antibacterial activities |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Nor, | HEK293 |
| 4558- | AgNPs, | Role of Oxidative and Nitro-Oxidative Damage in Silver Nanoparticles Cytotoxic Effect against Human Pancreatic Ductal Adenocarcinoma Cells |
| - | in-vitro, | PC, | PANC1 |
| 4541- | AgNPs, | RosA, | Eco-friendly synthesis of silver nanoparticles: multifaceted antioxidant, antidiabetic, anticancer, and antimicrobial activities |
| - | in-vitro, | Nor, | WI38 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | PC, | PANC1 |
| 375- | AgNPs, | ALA, | Alpha-Lipoic Acid Prevents Side Effects of Therapeutic Nanosilver without Compromising Cytotoxicity in Experimental Pancreatic Cancer |
| - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vivo, | NA, | NA |
| 1563- | Api, | MET, | Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells |
| - | in-vitro, | Nor, | HDFa | - | in-vitro, | PC, | AsPC-1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP | - | in-vivo, | NA, | NA |
| 2003- | Ash, | Withaferin A Induces Cell Death Selectively in Androgen-Independent Prostate Cancer Cells but Not in Normal Fibroblast Cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Nor, | TIG-1 | - | in-vitro, | PC, | LNCaP |
| 5836- | CAP, | In vitro and in vivo induction of apoptosis by capsaicin in pancreatic cancer cells is mediated through ROS generation and mitochondrial death pathway |
| - | vitro+vivo, | PC, | AsPC-1 | - | in-vitro, | PC, | Bxpc-3 |
| 2014- | CAP, | Role of Mitochondrial Electron Transport Chain Complexes in Capsaicin Mediated Oxidative Stress Leading to Apoptosis in Pancreatic Cancer Cells |
| - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | Nor, | HPDE-6 | - | in-vivo, | PC, | AsPC-1 |
| 6085- | CHOC, | Epicatechin-rich cocoa polyphenol inhibits Kras-activated pancreatic ductal carcinoma cell growth in vitro and in a mouse model |
| - | in-vivo, | PC, | NA |
| 1580- | Citrate, | Citrate activates autophagic death of prostate cancer cells via downregulation CaMKII/AKT/mTOR pathway |
| - | in-vitro, | Pca, | PC3 | - | in-vivo, | PC, | NA | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | WPMY-1 |
| 2309- | EGCG, | Chemo, | Targeting Glycolysis with Epigallocatechin-3-Gallate Enhances the Efficacy of Chemotherapeutics in Pancreatic Cancer Cells and Xenografts |
| - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | Nor, | HPNE | - | in-vitro, | PC, | PANC1 | - | in-vivo, | NA, | NA |
| 2860- | FIS, | Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress- and mitochondrial stress-dependent pathways |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | Nor, | hTERT-HPNE | - | in-vivo, | NA, | NA |
| 4509- | GLA, | Gamma-linolenic Acid (GLA) sensitizes pancreatic cancer cells to gemcitabine |
| - | in-vitro, | PC, | PANC1 |
| 4976- | Nimb, | Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition |
| - | vitro+vivo, | PC, | NA |
| 2061- | PB, | Chemo, | Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | COLO357 | - | in-vitro, | PC, | Bxpc-3 |
| 1674- | PBG, | SDT, | HPT, | Study on the effect of a triple cancer treatment of propolis, thermal cycling-hyperthermia, and low-intensity ultrasound on PANC-1 cells |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | Nor, | H6c7 |
| 1888- | VitB1/Thiamine, | DCA, | High Dose Vitamin B1 Reduces Proliferation in Cancer Cell Lines Analogous to Dichloroacetate |
| - | in-vitro, | PC, | SK-N-BE | - | NA, | PC, | PANC1 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:21 Cells:% prod#:% Target#:1110 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid